These models, previously used for neurological disorders like Parkinson’s disease (PD) (Kim et al., 2024), could be adapted to explore the impact of HGPRT deficiency on neural development and function, while high-throughput screening in these systems could help identify novel drugs to alleviate the neurological symptoms of LNS. This evidence concerns the gene HPRT1 and Lesch-Nyhan syndrome.